NEWS
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
Positive
Working capital increased by $19.5M from December 2023
Raised $12.5M in capital during Q3 2024
Net loss decreased by 46% YoY to $3.2M
R&D expenses reduced by $2.5M YoY
Secured European patents for CTx-1301 in up to 30 territories
Regained Nasdaq compliance with $1.00 minimum bid requirement
Negative
Accumulated deficit increased to $102.4M
Operating loss of $3.3M in Q3 2024
Cash position of $10M may require additional funding beyond Q3 2025
Working capital increased by $19.5M from December 2023
Raised $12.5M in capital during Q3 2024
Net loss decreased by 46% YoY to $3.2M
R&D expenses reduced by $2.5M YoY
Secured European patents for CTx-1301 in up to 30 territories
Regained Nasdaq compliance with $1.00 minimum bid requirement
Negative
Accumulated deficit increased to $102.4M
Operating loss of $3.3M in Q3 2024
Cash position of $10M may require additional funding beyond Q3 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2605Followers
107Following
28KVisitors
Follow
152338936 : Isn't this news from September?
Jaguar8 OP 152338936 : No
Jaguar8 OP 152338936 : Look at news tab.its from SEC
152338936 : @Jaguar8 thanks for the clarification